Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Filings indexed 684 across all filing types
Latest filing 2026-01-08 Board/Management Inform…
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
Cambio de Secretaria y Vicesecretaria del Consejo de Administración.
Board/Management Information Classification · 100% confidence The document is a formal communication from Grifols, S.A. regarding changes to the composition of its Board of Directors' secretarial roles. It explicitly mentions the appointment of new individuals to the positions of Secretary and Deputy Secretary of the Board of Directors. This falls directly under the category of board and management changes.
2026-01-08 Spanish
6-K Filing
Foreign Filer Report
2026-01-08 English
FORM 6-K
Foreign Filer Report
2025-12-16 English
La EMA ha emitido el Certificado de Conformidad con la legislación comunitaria para el plasma suministrado por Grifols Egypt for Plasma Derivatives.
Regulatory Filings Classification · 95% confidence The document is a formal communication from Grifols, S.A. to the Spanish securities market regulator (CNMV) under Article 227 of the Securities Market Law. It announces a specific regulatory milestone: the receipt of an EMA Certificate of Conformity for plasma from their Egyptian joint venture. As it is a regulatory announcement regarding a specific corporate development that does not fit into financial reporting, dividend, or governance categories, it is classified as a general regulatory filing.
2025-12-16 Spanish
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-12 English
FORM 6-K
Foreign Filer Report
2025-11-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.